CClinicalTrials.gg
RecruitingNCT07061366BB-EPUpdated Mar 11, 2026

The Use of the Bambi-Belt in Exteremly Preterm Infants: an Implementation Study.

An observational study in Preterm and Monitoring, sponsored by Maxima Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged Up to 1 Week. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Maxima Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
Up to 1 Week
Sex
All
01

Study summary

This observational, non-interventional cohort study evaluates the clinical use of the Bambi Belt-a CE-certified, wireless device for non-invasive heart rate and respiration monitoring-in extremely preterm infants (\<26 weeks gestation). 15 infants with intact skin and age \<24 hours will be monitored using the Bambi Belt during the first ten days of life. Primary outcomes include ease of use (application, signal stability), skin tolerance, and user experience (nurses and parents). Standard care remains unchanged. Data will be collected via clinical records and evaluation forms.

Read the detailed description

The Bambi Belt is a CE-certified, wireless monitoring device designed for continuous, non-invasive measurement of heart rate and respiration in neonates. Developed and validated in our center, it offers several advantages over traditional adhesive electrodes, including reduced skin irritation, improved comfort during kangaroo care, and easier handling of the infant. These features are particularly relevant for extremely preterm infants (\<26 weeks gestation), whose skin is highly vulnerable and for whom standard electrodes often pose clinical challenges.

Following a successful implementation phase in the general neonatal population, this study aims to evaluate the use of the Bambi Belt specifically in extremely preterm infants. Because of the low prevalence of this group, targeted implementation has not yet occurred. This observational cohort study will include 15 infants who meet the following inclusion criteria: gestational age \<26 weeks, postnatal age \<24 hours, and intact skin.

The Bambi Belt will be used as the standard method for heart rate and respiration monitoring during the first ten days of life. All other aspects of care remain unchanged. Outcomes will focus on:

Ease of use: including the ease of application, signal stability, and frequency of repositioning.

Skin tolerance: assessment of any skin reactions that necessitate switching back to conventional electrodes.

User experience: qualitative feedback from nurses and parents, collected via brief evaluation forms.

Clinical data will be obtained from the hospital's electronic patient record system (EPD/DWH). All data will be coded and processed according to GDPR and institutional guidelines. Parents will provide informed consent, including optional consent for anonymous data sharing with the device manufacturer (Bambi Medical).

This study is classified as non-WMO research, based on the minimal risk to the patient and the fact that the device is CE-marked and used within its intended purpose. The prior implementation phase has already been reviewed and approved as non-WMO by our local ethics review committee

02

Conditions studied

  • Preterm
  • Monitoring

Browse trials for

Keywords

  • wireless
  • monitoring
  • heart rate
03

Who can participate

Ages eligible
Up to 1 Week
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Extremely preterm infants in NICU

Eligibility criteria

Inclusion Criteria: Preterm born \<26 weeks; first week of life -

Exclusion Criteria: skin integrity problems prior to study, palliative care.

-

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • Extremely preterm infants
05

What researchers measure

Primary outcomes

  1. Ease of use

    ease of application according to score of nurse.

    Time frame: As long as belt is worn (10 days)

  2. Skin integrity

    any skin reactions that necessitate a switch back to conventional electrodes

    Time frame: as long as belt is worn (10 days)

  3. User experience

    feedback from nurses and parents, collected through brief evaluation forms

    Time frame: From belt is worn till month after

  4. Signal stability

    Precentage of time were reliable respiratory and heart rate signal is collected

    Time frame: during 10 days (study period wearing belt)

06

Study locations

2 of 2 sites recruiting
  • Amsterdam UMC
    Amsterdam, Netherlands
    • Gerard J Hutten, MD, PhD · Contact · g.j.hutten@amsterdamumc.nl · +3120 - 566 9111
    • Gerard J Hutten, MD PhD · Principal investigator
    Recruiting
  • Maxima Medical Centre
    Veldhoven, 5504 DB, Netherlands
    Recruiting
07

References and documents

Publications

  • Scholten AWJ, Zhan Z, Niemarkt HJ, Vervoorn M, van Leuteren RW, de Jongh FH, van Kaam AH, Heuvel ERVD, Hutten GJ. Cardiorespiratory monitoring with a wireless and nonadhesive belt measuring diaphragm activity in preterm and term infants: A multicenter non-inferiority study. Pediatr Pulmonol. 2023 Dec;58(12):3574-3581. doi: 10.1002/ppul.26695. Epub 2023 Oct 5. PubMed 37795597 ↗
  • Lorente Flores CM, Zhan Z, Scholten AWJ, Hutten GJ, Vervoorn M, Niemarkt HJ. The Effects of a New Wireless Non-Adhesive Cardiorespiratory Monitoring Device on the Skin Conditions of Preterm Infants. Sensors (Basel). 2024 Feb 16;24(4):1258. doi: 10.3390/s24041258. PubMed 38400415 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07061366
Lead sponsor
Maxima Medical Center
Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Responsible party
Hendrik Niemarkt (Principal investigator, Maxima Medical Center) — Principal investigator
First posted
Jul 11, 2025
Start date
Aug 10, 2025
Primary completion
Jul 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Hendrik J Niemarkt, MD PhD
Contact
hendrik.niemarkt@mmc.nl
+31621825013

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion